U.S. Drug, OTC Drug and Pharmaceutical Imports
A practical guide to U.S. FDA compliance for domestic and foreign manufacturers, active pharmaceutical ingredient suppliers, exporters, importers, private-label distributors, wholesale distributors and other companies participating in the American drug supply chain.
Importing Pharmaceuticals into the United States Requires More Than Shipping Documents
The United States is one of the world’s largest and most closely regulated pharmaceutical markets. Foreign manufacturers supply finished prescription products, over-the-counter medicines, active pharmaceutical ingredients, excipients and other components used throughout the American healthcare system. Domestic companies also rely on global contract manufacturers, packagers, relabelers, testing laboratories and logistics providers. This international structure creates commercial opportunity, but it also creates a long chain of regulatory responsibilities.
A drug shipment is not considered compliant merely because a customs broker can transmit an entry or because the foreign manufacturer has obtained an establishment registration number. FDA evaluates whether the product may be legally marketed, whether the establishment and products are properly registered and listed, whether required applications or OTC monograph conditions are satisfied, whether the labeling is accurate, and whether the manufacturing operation complies with current good manufacturing practice requirements.
Imported human drugs must meet the same federal standards as drugs produced in the United States. FDA electronically screens imported products and may request documents, examine the shipment, collect samples, detain the entry or refuse admission when the agency has evidence that the drug appears adulterated, misbranded, unapproved or otherwise noncompliant. The importer, manufacturer, consignee and regulatory representatives therefore need a coordinated compliance plan before commercial shipments begin.
This article explains the principal compliance obligations that affect prescription drugs, OTC drugs, APIs and related pharmaceutical products. It also describes how experienced U.S. FDA consultants can help companies prepare registrations, listings, labels, import documentation, quality systems and regulatory responses.
Understanding the U.S. Drug Import Framework
Drug import compliance involves overlapping responsibilities under the Federal Food, Drug, and Cosmetic Act, FDA regulations, approved applications, OTC monograph requirements, CGMP rules, import procedures and supply-chain laws.
Approved or Otherwise Lawfully Marketed
Most prescription drug products require an approved New Drug Application, Abbreviated New Drug Application or another legally recognized pathway before commercial distribution. The imported product must correspond to the approved application, including its formulation, strength, dosage form, manufacturing sites, labeling and other approved conditions.
Monograph or Application Pathway
An OTC product may be marketed under an applicable OTC drug monograph when every relevant condition is satisfied. The active ingredient, dosage form, strength, indications, warnings, directions, testing and labeling must remain within the monograph framework. Products outside those conditions may require an approved application.
Identity, Intended Use and Quality Controls
Active pharmaceutical ingredients and other drug components are FDA-regulated articles. Their import documentation should accurately identify the material, manufacturer, intended pharmaceutical use, consignee and associated application or lawful commercial purpose. API operations should follow appropriate CGMP principles.
Important distinction: FDA establishment registration, drug listing, assignment of a National Drug Code or appearance in an FDA database does not by itself constitute product approval and does not prove that a drug may be legally marketed.
Drug Establishment Registration, U.S. Agent and Drug Listing
Domestic and foreign establishments involved in manufacturing, repacking or relabeling drugs for U.S. commercial distribution generally must register with FDA. Drug products in commercial distribution must also be listed electronically. Foreign establishments whose drugs are imported or offered for import must register before offering the drug for import, renew annually, identify a U.S. Agent and provide information about known importers.
Registration data helps FDA locate establishments, plan inspections, evaluate imports, conduct surveillance, manage recalls and identify participants in the drug supply chain. Listing data provides product-specific information such as the proprietary and established names, dosage form, route, strength, active ingredients, labeling and manufacturing relationships.
Register the Establishment
Submit accurate ownership, facility, operation and contact information electronically. Confirm the establishment type and every drug-related activity performed at the site.
Designate a U.S. Agent
A foreign drug establishment designates a single U.S. Agent who resides or maintains a place of business in the United States and serves as an FDA communication contact.
List Commercial Drugs
Prepare and submit complete product data and Structured Product Labeling information for prescription, OTC, unfinished and applicable compounded products.
Maintain the Records
Renew establishment registration annually and update listing information when products, labels, manufacturing arrangements or marketing status change.
The registration renewal window generally runs from October 1 through December 31 each year. A company should not wait until the renewal period to correct ownership errors, outdated contacts, missing importer information or inconsistent product listings. Import screening may compare the entry data against FDA registration and listing records, so small discrepancies can delay a shipment.
Prescription Drug Import Compliance
Prescription drug imports receive close regulatory scrutiny because the product’s legal market status, manufacturing controls and labeling directly affect patient safety. Before importation, the responsible parties should determine which approved application or lawful exemption supports distribution. The imported drug should be manufactured at an establishment recognized in the applicable regulatory submission and under the conditions authorized by FDA.
The product, packaging and shipping records should consistently identify the drug name, strength, dosage form, manufacturer, application number when applicable, NDC information, lot number and expiration dating. Entry data must accurately describe the article. Vague descriptions such as “health products,” “samples” or “chemicals” can create questions and may prevent FDA from efficiently matching the shipment to the correct regulatory record.
Prescription drug labeling must comply with applicable professional labeling, container and carton requirements, medication guide obligations and other product-specific conditions. Promotional claims cannot overstate efficacy, omit material risk information or imply broader use than the approved indication.
Pre-Import Prescription Drug Review
- ▷Confirm the supporting NDA, ANDA, BLA or other lawful pathway.
- ▷Verify that the foreign manufacturing site is properly registered.
- ▷Match the drug listing and SPL data to the shipped product.
- ▷Review carton, container, prescribing and patient labeling.
- ▷Confirm lot release, testing, stability and expiration records.
- ▷Prepare accurate FDA and customs entry data before departure.
OTC Drug Imports and the Monograph System
OTC status does not mean that a product is lightly regulated. OTC medicines include products such as certain sunscreens, antacids, pain relievers, cough and cold preparations, acne treatments, skin protectants and topical antimicrobials. Each product must have a legally valid marketing basis.
An OTC monograph functions like a rulebook for a therapeutic category. It describes the active ingredients, uses, concentrations, dosage forms, routes of administration, directions, warnings and other conditions under which a drug may be marketed without an individual approved application. A manufacturer cannot select only the convenient portions of a monograph. All applicable conditions must be satisfied.
Formula Review
Confirm every active ingredient, concentration and dosage form. Determine whether inactive ingredients are suitable and whether they interfere with safety, effectiveness or required testing.
Drug Facts Label
Review the standardized Drug Facts format, active ingredient statement, purpose, uses, warnings, directions, inactive ingredients and required contact information.
Claims Review
Website, marketplace, social media and package claims must remain consistent with the lawful OTC conditions. Disease claims outside the monograph can turn an apparently ordinary OTC product into an unapproved new drug.
Testing Program
Identity, strength, purity, quality and performance testing should match the product and category. Certain products require specific effectiveness or quality testing.
Facility Compliance
OTC drug manufacturers remain subject to drug CGMP requirements, FDA inspection, establishment registration, drug listing and enforcement controls.
OMUFA Considerations
Companies marketing OTC monograph drugs should assess whether facility fee or other OTC Monograph User Fee Program obligations apply to their operations.
Active Pharmaceutical Ingredients, Excipients and Bulk Drug Materials
APIs are essential inputs in drug manufacturing and are frequently sourced internationally. Importers should not assume that a bulk powder, liquid or intermediate escapes FDA oversight because it is not yet packaged as a finished medicine. FDA may examine the material’s identity, declared intended use, manufacturer, quality status, application relationship and destination.
API suppliers should maintain a quality system appropriate to the stage of manufacture. Important controls include supplier qualification, raw-material testing, process validation, impurity control, equipment cleaning, deviation management, change control, laboratory governance, data integrity, stability, packaging, storage and distribution. Certificates of analysis should be supported by reliable testing and should not substitute for a documented quality program.
Common API Import Risks
- ▷Incorrect manufacturer or shipper information.
- ▷Unclear intended use or end-user documentation.
- ▷Mismatch with an approved application or listing.
- ▷Unsupported compendial or purity claims.
- ▷Inadequate impurity, solvent or contamination controls.
Recommended Supporting Records
- ■Commercial invoice and precise product description.
- ■Certificate of analysis and lot identification.
- ■Manufacturer registration and facility information.
- ■Letter of authorization or intended-use statement.
- ■Application, DMF or customer relationship information when applicable.
Current Good Manufacturing Practice and FDA Inspection Readiness
Drug CGMP requirements establish minimum standards for the methods, facilities and controls used in manufacturing, processing, packing and holding drug products. FDA inspections may evaluate whether a facility can consistently produce drugs that meet identity, strength, quality and purity requirements.
Inspection readiness should be continuous. A company that begins organizing its documents only after receiving an inspection notice may discover that procedures do not match actual practice, investigations are incomplete, laboratory controls are weak or electronic records cannot demonstrate data integrity.
Quality Unit Authority
The quality unit should have sufficient independence and documented authority to approve or reject components, procedures, specifications, deviations, investigations, batch records and finished products.
Laboratory Controls
Methods should be appropriate and validated or verified as required. Records should preserve complete data, calculations, chromatograms, audit trails, invalidated results and investigation conclusions.
Production Controls
Master and executed batch records should document actual operations, yields, in-process controls, reconciliation, equipment use and personnel performance.
Investigations and CAPA
Deviations, complaints, out-of-specification results and recurring trends require scientifically sound investigations, root-cause analysis and effective corrective and preventive actions.
Supplier Oversight
Manufacturers remain responsible for the quality of components and contracted activities. Supplier qualification should be risk-based, documented and periodically reassessed.
Records and Data Integrity
FDA expects complete, consistent and accurate records. Controls should protect paper and electronic data against omission, alteration, backdating, unauthorized access and unexplained deletion.
Import Entry, FDA Screening, Detention and Refusal
FDA-regulated products are electronically screened when import entries are transmitted. FDA may release the shipment without examination, request additional information, conduct a physical examination, collect samples or detain the product. The admissibility decision is based on the product and the information available at the time of entry.
Product and Party Verification
Confirm the actual manufacturer, shipper, importer, consignee and ultimate destination. Ensure that facility identifiers and business names match FDA records.
Entry Data Preparation
Provide accurate product descriptions, product codes, quantities, country information and regulatory identifiers. The customs broker should receive the compliance data before filing.
Document Response
When FDA requests records, submit a concise and organized package addressing the exact issue. Relevant documents may include labels, registration evidence, listings, applications, invoices, COAs, batch records and intended-use statements.
Detention Strategy
A Notice of FDA Action may identify the apparent violation and response deadline. The company should promptly evaluate whether evidence can overcome the appearance of violation, whether relabeling or reconditioning is legally available, or whether export or destruction is necessary.
Corrective Action
After resolving the entry, investigate the cause. Correct registration, listing, label, broker instructions, supplier controls or commercial documents before the next shipment.
Import Alert risk: Repeated violations, serious CGMP deficiencies or unresolved evidence may result in detention without physical examination. Removal from an import alert generally requires a documented corrective strategy and evidence that future products will comply.
Labeling, Misbranding and Pharmaceutical Promotion
A drug is misbranded when its labeling fails to include required information, is false or misleading, lacks adequate directions or warnings, misstates the manufacturer or distributor, or otherwise violates applicable requirements. Promotional communications are also relevant. Websites, sponsored links, social media posts, email campaigns, brochures, marketplace listings and sales presentations can create regulatory exposure.
Identity and Statement of Contents
The label should clearly identify the drug, dosage form, strength and package quantity using consistent terminology across the container, carton, listing and commercial documents.
Directions, Uses and Warnings
OTC labels must follow applicable Drug Facts requirements. Prescription labeling must remain consistent with approved conditions and include required risk information.
Manufacturer and Distributor Details
Company names, roles and addresses must be accurate. Private-label relationships should be reflected properly without obscuring the responsible manufacturer.
NDC Presentation
NDC information should correspond to the current listing. The presence of an NDC must never be promoted as proof of FDA approval.
Balanced Promotion
Promotional communications should not exaggerate benefits, minimize risks, omit material facts or imply uses broader than the approved or lawful OTC indications.
Digital Marketplace Controls
Amazon, TikTok Shop, Shopify and other online channels may display claims created by marketing teams, resellers or automated feeds. Regulatory review should cover the live public-facing content.
Importer, Distributor and Supply-Chain Responsibilities
Importers and distributors are not passive transportation parties. Their activities can affect whether products are lawfully introduced into interstate commerce, properly stored, traceable and protected against diversion or counterfeiting. Companies should clearly allocate regulatory responsibilities in written agreements while recognizing that a contract cannot eliminate obligations imposed by law.
For certain prescription drugs, the Drug Supply Chain Security Act establishes product tracing and verification requirements for manufacturers, repackagers, wholesale distributors and dispensers. Authorized trading partners must exchange required transaction information and maintain systems capable of identifying and responding to suspect or illegitimate products. Wholesale distributors and third-party logistics providers may also face state licensure and FDA reporting obligations.
Importer
Coordinates entry, ensures data accuracy, responds to FDA requests and verifies that the foreign source and product have an appropriate compliance basis.
Distributor
Controls storage, handling, customer distribution, complaint escalation, recalls and marketplace representations.
Wholesale Distributor
Assesses licensure, authorized trading partner status, tracing systems and suspect-product procedures under applicable federal and state rules.
Third-Party Logistics Provider
Evaluates licensing, annual reporting, security, inventory controls and written allocation of responsibilities with product owners.
Common Compliance Failures That Disrupt Pharmaceutical Imports
Regulatory Record Failures
- ▷Expired or inaccurate establishment registration.
- ▷Missing U.S. Agent or outdated contact information.
- ▷Drug listing that does not match the commercial label.
- ▷Incorrect manufacturer, repacker or relabeler relationships.
- ▷Use of an NDC as a substitute for marketing authorization.
Product and Shipment Failures
- ▷Unapproved prescription product or nonconforming OTC formula.
- ▷Claims that exceed approved or monograph conditions.
- ▷Incomplete Drug Facts or prescription labeling.
- ▷CGMP deficiencies or unreliable laboratory data.
- ▷Inaccurate entry descriptions and missing supporting documents.
Many import problems begin months before the product reaches a U.S. port. They may originate during formulation, contract manufacturing, label design, registration, listing or commercial onboarding. A pre-market compliance review is generally less expensive and disruptive than responding to detention, recall, warning letter or import alert consequences.
Services Provided by U.S. FDA Consultants
FDA consultants can help manufacturers, exporters, importers and distributors translate regulatory requirements into practical actions. The consultant’s role should be defined by the product, establishment activities, market pathway, quality maturity and import history. Consulting support does not replace the legal responsibilities of the regulated company, but it can reduce avoidable errors and improve communication among regulatory, quality, operations, logistics and commercial teams.
Regulatory Classification
Determine whether the article is a prescription drug, OTC drug, API, excipient, cosmetic, dietary supplement, medical device, biologic or combination product and identify the likely marketing pathway.
Establishment Registration
Prepare initial registration, annual renewal, establishment activity updates, UFI review, ownership changes and foreign facility records.
U.S. Agent Service
Serve as the designated contact for a foreign drug establishment, receive FDA communications, facilitate contact and help coordinate timely responses.
Drug Listing and SPL
Prepare or review electronic listings, NDC data, labeling files, product updates, discontinuation records and manufacturer-distributor relationships.
OTC Monograph Assessment
Compare the formula, dosage form, indications, warnings, directions and testing program against the applicable OTC monograph conditions.
Label and Claims Review
Review containers, cartons, Drug Facts panels, websites, marketplace pages, brochures and advertising for potential misbranding or unapproved claims.
CGMP Gap Assessment
Evaluate SOPs, quality-unit controls, laboratory systems, investigations, CAPA, supplier qualification, stability, validation and data integrity.
Inspection Readiness
Conduct mock inspections, organize document rooms, train personnel, prepare facility tours and develop procedures for managing investigator requests.
Import Compliance Review
Review product codes, entry data, invoices, labels, registrations, listings and supporting evidence before the commercial shipment departs.
Detention Assistance
Analyze FDA notices, assemble evidence, draft responses, coordinate with brokers and counsel, and evaluate reconditioning, export or destruction options.
Import Alert Remediation
Develop corrective-action plans, organize evidence of sustained compliance and prepare removal submissions when the company can satisfy FDA expectations.
Distributor Compliance
Support complaint procedures, recall readiness, supplier agreements, storage controls, DSCSA assessments and authorized trading partner reviews.
A Practical Pre-Market Compliance Roadmap
Companies planning to introduce a foreign-manufactured pharmaceutical product should begin with a documented regulatory assessment. The following sequence helps prevent marketing, manufacturing and import teams from moving in different directions.
Define the Product
Document the ingredients, strength, dosage form, intended use, claims, target users and presentation. Confirm whether the article is a drug and whether other FDA categories are involved.
Confirm the Marketing Pathway
Identify the approved application, OTC monograph or other legal basis. Do not proceed with registration and label production until the pathway is clear.
Map Every Establishment
List manufacturers, API sites, contract packagers, relabelers, laboratories, warehouses and distributors. Determine registration, listing and inspection implications for each party.
Build the Quality and Labeling Package
Complete specifications, testing, batch documents, stability support, supplier controls, labels and promotional review.
Prepare the Import Data Set
Give the customs broker and importer a verified product description, FDA product code, manufacturer details, regulatory identifiers and supporting document package.
Monitor and Maintain
Renew registrations, update listings, investigate complaints, review changes, assess suppliers, maintain DSCSA controls where applicable and remain inspection-ready.
FDA Compliance Is a Continuous Market-Access Function
U.S. pharmaceutical import compliance is not a single registration task. It is a connected system that begins with the product’s legal marketing status and continues through manufacturing, testing, labeling, registration, listing, import entry, distribution, surveillance and regulatory maintenance.
Foreign manufacturers need accurate establishment records, a responsive U.S. Agent, compliant drug listings and an inspection-ready quality system. Importers need reliable entry data and a method for confirming that the product and source are lawful. Distributors and other trading partners need appropriate storage, complaint, recall, tracing and supplier controls. Marketing teams need guardrails that prevent unapproved claims and misleading statements.
Companies that treat these activities as one coordinated program are better positioned to prevent detention, reduce shipment delays, answer FDA questions and protect long-term access to the U.S. market. An experienced FDA consultant can help organize that program, identify gaps before launch and support corrective action when a compliance problem has already occurred.
Prepare Your Drug Products and Facilities for the U.S. Market
Request assistance with FDA drug establishment registration, U.S. Agent representation, drug listing, OTC monograph review, labeling, CGMP readiness, import documentation or detention response.
Selected Official Regulatory Resources
FDA: Importing Human Drugs | FDA: General Requirements for Importing Human Drugs | FDA: Registration and Listing | FDA: OTC Drug Monographs | FDA: Current Good Manufacturing Practice Regulations | FDA: Drug Supply Chain Security ActThis educational article is not legal advice and does not replace product-specific review of the FD&C Act, 21 CFR, approved applications, OTC monographs, FDA guidance, state licensing requirements or current agency policy.
